Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

The results of the International Randomized Study of Interferon and STI571 (IRIS) trial indicate that in patients with chronic phase CML treated with first line imatinib, achievement of a complete or partial cytogenetic response (CCyR or PCyR) at 12 months is associated with a significantly better progression-free survival (PFS). Second …

gleevec
basophils
chronic phase chronic myeloid leukemia
hydroxyurea
philadelphia chromosome
  • 10 views
  • 24 Mar, 2022
  • 1 location
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

1:1 ratio to receive imatinib (Gleevec) for 2 more years (Arm A) or to stop imatinib (Arm B). The study participants are required to have histologically verified GIST with a high risk of GIST

gleevec
gastrointestinal stromal tumor
imatinib
KIT
immunomodulators
  • 7 views
  • 23 Mar, 2022
  • 1 location
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

The purpose of this study is to evaluate the safety and efficacy of the tyrosine kinase inhibitor, imatinib mesylate (Gleevec ) in reducing peripheral blood eosinophilia in patients with the

  • 4 views
  • 30 Jun, 2022
  • 1 location
A Study for Tyrosine Kinase Inhibitors Discontinuation

Treatment of Chronic Myeloid Leukemia (CML) has been revolutionized by the use of tyrosine kinase inhibitors including imatinib mesylate (Gleevec, Novartis Laboratories). Two other inhibitors of

myeloid leukemia
remission
imatinib
chronic myeloid leukemia
nilotinib
  • 0 views
  • 22 Jan, 2021
  • 1 location